SpyGlass Pharma has randomized the first patients into two registrational Phase III trials, SGP-005 and SGP-006, evaluating its Bimatoprost Drug Pad–IOL System in patients with open-angle glaucoma or ocular hypertension undergoing cataract surgery. Each prospective, multicenter, randomized, masked, controlled study will enroll roughly 400 participants and test non-inferiority versus a standard intraocular lens plus twice-daily timolol drops. The co-primary endpoints are the time-matched change in mean IOP from baseline and the proportion achieving the best-corrected distance visual acuity of 20/40 or better. Secondary measures include mean IOP change over time, time to introduction of postoperative IOP-lowering medications, and the number of medications introduced. Participants will be followed for up to 36 months to assess durability and long-term safety.
The core move is a full pivot into late-stage development of an intraoperative, sustained-delivery glaucoma therapy embedded in an IOL. The system attaches non-biodegradable drug pads to a standard cataract lens to provide up to 3 years of bimatoprost release, aiming to reduce the burden of post-surgical topical therapy adherence. SpyGlass is continuing long-term follow-up from its Phase I/II program and signals a drug-led combination product pathway, pointing to an eventual NDA filing rather than a device PMA.
Strategically, SpyGlass is betting on the cataract operating room as the entry point for glaucoma management, seeking adoption among the majority of cataract surgeons who do not routinely perform MIGS. The non-inferiority comparator of timolol, while conventional for pivotal glaucoma trials, sets a relatively moderate efficacy bar compared with prostaglandin analogs and newer sustained-delivery implants. That choice underscores a pragmatic regulatory approach but raises the bar on demonstrating clinical and economic differentiation: durability without clinic visits for refills, stable vision outcomes, and fewer postoperative medications will need to be clear. The three-year dosing horizon directly challenges topical adherence and positions the product against prior intracameral options that have faced durability or safety limitations.
Operationally, these studies will concentrate activity in high-volume cataract centers, with masking typically applied to outcome assessors rather than surgeons. Sites will need standardized protocols for postoperative rescue medications and consistent IOP measurement schedules to avoid bias in time-matched analyses. The 36-month follow-up demands robust retention and data quality support, favoring CROs and vendors with ophthalmic surgery logistics, imaging, and endothelial cell monitoring capabilities. On the manufacturing side, combination product controls for drug release kinetics, IOL optics, sterilization, and shelf-life will be closely scrutinized, with implications for scale-up and site inventory management if the program advances.
The commercial and policy arc will hinge on whether regulators view the integrated IOL-drug product as meeting a meaningful unmet need at the time of cataract surgery and how payers classify it within bundled ASC payments. Precedent for separate payment or NTIOL-like pathways will be pivotal for adoption. Near term, watch for interim IOP curves at 6–12 months, rescue-free rates, endothelial safety signals, cystoid macular edema incidence, and device stability. Clarity on the review center for this combination product, manufacturing readiness for consistent drug elution, and the reimbursement construct will determine the trajectory as much as the efficacy readout. If non-inferiority is achieved with convincing durability and safety, the next competitive question will be head-to-head value versus MIGS and approved sustained-delivery implants in the cataract setting.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
